Sona Nanotech Receives ‘Deprioritization’ from FDA; Health Canada Evaluation Continues

You may also like

Sona Nanotech to Showcase its THT Cancer Therapy at NCL 20th Anniversary Symposium and Provides Corporate Update

Sona Nanotech Issued Patent and Appoints New Board Member

Sona Nanotech Grants Options

Sona Nanotech Closes Private Placement Financing to Raise $1,643,750 in Gross Proceeds